Drug For Triple-Negative Breast Cancer Treatment Received Fast Track Designation By FDA
News
Immunomedics, Inc. has announced its sacituzumab govitecan research received the U.S. Food and Drug Administration (FDA) designation of Fast Track development program for the treatment of triple negative breast cancer ... Read more